Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Alzheimer's Disease

  Free Subscription


Articles published in Ann Neurol

Retrieve available abstracts of 82 articles:
HTML format



Single Articles


    March 2021
  1. PETERSEN RC, Wiste HJ, Weigand SD, Fields JA, et al
    NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages.
    Ann Neurol. 2021 Mar 26. doi: 10.1002/ana.26071.
    PubMed     Abstract available


  2. BUCIUC M, Whitwell JL, Kasanuki K, Graff-Radford J, et al
    Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype.
    Ann Neurol. 2021;89:520-533.
    PubMed     Abstract available


    February 2021
  3. KONIJNENBERG E, Tomassen J, den Braber A, Ten Kate M, et al
    The onset of preclinical Alzheimer's disease in monozygotic twins.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26048.
    PubMed     Abstract available


  4. FILIPPONE A, Pratico D
    Endosome dysregulation in Down syndrome: a potential contributor to Alzheimer's disease pathology.
    Ann Neurol. 2021 Feb 6. doi: 10.1002/ana.26042.
    PubMed     Abstract available


  5. MEEKER KL, Wisch JK, Hudson D, Coble D, et al
    Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework.
    Ann Neurol. 2021;89:254-265.
    PubMed     Abstract available


    December 2020
  6. RAJAN KB, Aggarwal NT, McAninch EA, Weuve J, et al
    Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study.
    Ann Neurol. 2020;88:1065-1076.
    PubMed     Abstract available


    November 2020
  7. LESMAN-SEGEV OH, La Joie R, Iaccarino L, Lobach I, et al
    Diagnostic Accuracy of Amyloid versus FDG PET in Autopsy-Confirmed Dementia.
    Ann Neurol. 2020 Nov 20. doi: 10.1002/ana.25968.
    PubMed     Abstract available


  8. BUCKLEY RF, Scott MR, Jacobs HIL, Schultz AP, et al
    Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline.
    Ann Neurol. 2020;88:921-932.
    PubMed     Abstract available


    October 2020
  9. TAN S, Baggio D, Shortt J, Ko B, et al
    Cardiovascular Safety of Nilotinib in Alzheimer's Disease.
    Ann Neurol. 2020 Oct 25. doi: 10.1002/ana.25947.
    PubMed    


  10. MOUSSA C
    Reply to Cardiovascular Safety of Nilotinib in Alzheimer's Disease.
    Ann Neurol. 2020 Oct 25. doi: 10.1002/ana.25946.
    PubMed    


  11. NOYCE AJ, Klein C
    Genetic risk of Alzheimer's disease - Sleepless with the enemy.
    Ann Neurol. 2020 Oct 18. doi: 10.1002/ana.25938.
    PubMed    


  12. ESPAY AJ, Marsili L, Mahajan A, Sturchio A, et al
    Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25923.
    PubMed     Abstract available


    September 2020
  13. ANDREWS SJ, Fulton-Howard B, O'Reilly P, Marcora E, et al
    Causal associations between modifiable risk factors and the Alzheimer's phenome.
    Ann Neurol. 2020 Sep 29. doi: 10.1002/ana.25918.
    PubMed     Abstract available


  14. LENG Y, Ackley SF, Glymour MM, Yaffe K, et al
    Genetic risk of Alzheimer's disease and sleep duration in non-demented elders.
    Ann Neurol. 2020 Sep 20. doi: 10.1002/ana.25910.
    PubMed     Abstract available


  15. LAO PJ, Gutierrez J, Keator D, Rizvi B, et al
    Alzheimer's-related cerebrovascular disease in Down syndrome.
    Ann Neurol. 2020 Sep 18. doi: 10.1002/ana.25905.
    PubMed     Abstract available


    August 2020
  16. GHIRELLI A, Tosakulwong N, Weigand SD, Clark HM, et al
    Sensitivity-specificity of tau and Abeta PET in frontotemporal lobar degeneration.
    Ann Neurol. 2020 Aug 31. doi: 10.1002/ana.25893.
    PubMed     Abstract available


  17. MENGEL D, Janelidze S, Glynn RJ, Liu W, et al
    Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease.
    Ann Neurol. 2020 Aug 23. doi: 10.1002/ana.25885.
    PubMed     Abstract available


  18. HALPERIN JJ, Pascual-Leone A, Saper CB
    Symptomatic Hydrocephalus with Normal Cerebrospinal Pressure and Alzheimer's Disease.
    Ann Neurol. 2020 Aug 9. doi: 10.1002/ana.25871.
    PubMed    


    July 2020
  19. MULLER-SCHMITZ K, Krasavina-Loka N, Yardimci T, Lipka T, et al
    Normal pressure hydrocephalus associated with Alzheimer' disease.
    Ann Neurol. 2020 Jul 13. doi: 10.1002/ana.25847.
    PubMed     Abstract available


  20. NUNEZ C, Callen A, Lombardini F, Compta Y, et al
    Different Cortical Gyrification Patterns in Alzheimer's Disease and Impact on Memory Performance.
    Ann Neurol. 2020;88:67-80.
    PubMed     Abstract available


    June 2020
  21. ARVANITAKIS Z, Wang HY, Capuano AW, Khan A, et al
    Brain insulin signaling, Alzheimer's disease pathology, and cognitive function.
    Ann Neurol. 2020 Jun 18. doi: 10.1002/ana.25826.
    PubMed     Abstract available


  22. IRWIN DJ, Felder J, Coffey CS, Caspell-Garcia C, et al
    Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
    Ann Neurol. 2020 Jun 16. doi: 10.1002/ana.25811.
    PubMed     Abstract available


  23. SCARIONI M, Gami-Patel P, Timar Y, Seelaar H, et al
    Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology.
    Ann Neurol. 2020;87:950-961.
    PubMed     Abstract available


  24. BUCKLEY R, Pascual-Leone A
    Age-Related Cognitive Decline Is Indicative of Neuropathology.
    Ann Neurol. 2020;87:813-815.
    PubMed    


    May 2020
  25. TURNER RS, Hebron ML, Lawler A, Mundel EE, et al
    Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.
    Ann Neurol. 2020 May 28. doi: 10.1002/ana.25775.
    PubMed     Abstract available


  26. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.
    PubMed    


    April 2020
  27. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.
    PubMed    


    March 2020
  28. STRANDBERG TE, Tienari PJ, Kivimaki M
    Vascular and Alzheimer's disease in dementia.
    Ann Neurol. 2020 Mar 10. doi: 10.1002/ana.25715.
    PubMed    


    January 2020
  29. ZEYDAN B, Lowe VJ, Reichard RR, Przybelski SA, et al
    Imaging Biomarkers of Alzheimer's Disease in Multiple Sclerosis.
    Ann Neurol. 2020 Jan 22. doi: 10.1002/ana.25684.
    PubMed     Abstract available


  30. DESPA F, Goldstein LB, Biessels GJ
    Amylin as a Potential Link between Type 2 Diabetes and Alzheimer Disease.
    Ann Neurol. 2020 Jan 9. doi: 10.1002/ana.25668.
    PubMed    


    November 2019
  31. HANSEEUW BJ, Scott MR, Sikkes S, Properzi M, et al
    Evolution of anosognosia in Alzheimer's disease and its relationship to amyloid.
    Ann Neurol. 2019 Nov 21. doi: 10.1002/ana.25649.
    PubMed     Abstract available


  32. GUSTAVSSON AM, van Westen D, Stomrud E, Engstrom G, et al
    Midlife atherosclerosis and development of Alzheimer's or vascular dementia.
    Ann Neurol. 2019 Nov 12. doi: 10.1002/ana.25645.
    PubMed     Abstract available


  33. WILLIAMS DM, Finan C, Schmidt AF, Burgess S, et al
    Lipid lowering and Alzheimer's disease risk: a Mendelian randomization study.
    Ann Neurol. 2019 Nov 12. doi: 10.1002/ana.25642.
    PubMed     Abstract available


  34. PRINS S, Zhuparris A, Groeneveld GJ
    The Usefulness of Plasma Amyloid as a Prescreener for the Earliest Alzheimer Pathological Changes depends on the study population.
    Ann Neurol. 2019 Nov 1. doi: 10.1002/ana.25634.
    PubMed    


  35. VERBERK IMW, Teunissen CE, Van der Flier WM
    Reply to "The Usefulness of Plasma Amyloid as Prescreener of the earliest Alzheimer Pathological Changes depends on the study population".
    Ann Neurol. 2019 Nov 1. doi: 10.1002/ana.25633.
    PubMed    


    October 2019
  36. JAMES BD, Wilson RS, Capuano AW, Boyle PA, et al
    Hospitalization, Alzheimer's and Related Neuropathologies, and Cognitive Decline.
    Ann Neurol. 2019 Oct 15. doi: 10.1002/ana.25621.
    PubMed     Abstract available


    September 2019
  37. MENG Y, Abrahao A, Heyn CC, Bethune AJ, et al
    Glymphatics visualization after focused ultrasound induced blood-brain barrier opening in humans.
    Ann Neurol. 2019 Sep 16. doi: 10.1002/ana.25604.
    PubMed     Abstract available


    August 2019
  38. KUMMER BR, Diaz I, Wu X, Aaroe AE, et al
    Associations between cerebrovascular risk factors and parkinson disease.
    Ann Neurol. 2019 Aug 29. doi: 10.1002/ana.25564.
    PubMed     Abstract available


  39. MARTINEZ-VALBUENA I, Valenti-Azcarate R, Amat-Villegas I, Riverol M, et al
    Amylin as a potential link between type 2 diabetes and Alzheimer's disease.
    Ann Neurol. 2019 Aug 3. doi: 10.1002/ana.25570.
    PubMed     Abstract available


    July 2019
  40. SCHULTZ A, Kloet RW, Sohrabi HR, van der Weerd L, et al
    Amyloid Imaging of Dutch-type Hereditary Cerebral Amyloid Angiopathy Carriers.
    Ann Neurol. 2019 Jul 30. doi: 10.1002/ana.25560.
    PubMed     Abstract available


  41. WHARTON W, Kollhoff AL, Gangishetti U, Verble DD, et al
    IL-9 alterations linked to Alzheimer's disease in African Americans.
    Ann Neurol. 2019 Jul 4. doi: 10.1002/ana.25543.
    PubMed     Abstract available


    June 2019
  42. LEONENKO G, Shoai M, Bellou E, Sims R, et al
    Genetic risk for Alzheimer's disease is distinct from genetic risk for amyloid deposition.
    Ann Neurol. 2019 Jun 14. doi: 10.1002/ana.25530.
    PubMed     Abstract available


  43. YANG T, Dang Y, Ostaszewski B, Mengel D, et al
    Target Engagement in an Alzheimer Trial: Crenezumab Lowers Abeta Oligomers in CSF.
    Ann Neurol. 2019 Jun 5. doi: 10.1002/ana.25513.
    PubMed     Abstract available


    March 2019
  44. WADHWANI AR, Affaneh A, Van Gulden S, Kessler JA, et al
    Neuronal Apolipoprotein E4 increases cell death and p-tau release in Alzheimer's disease.
    Ann Neurol. 2019 Mar 6. doi: 10.1002/ana.25455.
    PubMed     Abstract available


    February 2019
  45. COUGHLIN D, Xie SX, Liang M, Williams A, et al
    Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
    Ann Neurol. 2019;85:259-271.
    PubMed     Abstract available


    January 2019
  46. PANZA F, Lozupone M, Seripa D, Imbimbo BP, et al
    Amyloid-beta Immunotherapy for Alzheimer's Disease - Is It Now A Long Shot...?
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25410.
    PubMed     Abstract available


  47. GABELLE A, Jaussent I, Bouallegue FB, Lehmann S, et al
    Reduced brain amyloid burden in elderly patients with narcolepsy type 1.
    Ann Neurol. 2019;85:74-83.
    PubMed     Abstract available


    December 2018
  48. HARRISON TM, La Joie R, Maass A, Baker SL, et al
    Longitudinal tau accumulation and atrophy in aging and Alzheimer's disease.
    Ann Neurol. 2018 Dec 31. doi: 10.1002/ana.25406.
    PubMed     Abstract available


    November 2018
  49. BOYLE PA, Yu L, Leurgans SE, Wilson RS, et al
    Attributable Risk of Alzheimer's Dementia Due to Age-Related Neuropathologies.
    Ann Neurol. 2018 Nov 12. doi: 10.1002/ana.25380.
    PubMed     Abstract available


    September 2018
  50. IHARA R, Vincent BD, Baxter MR, Franklin EE, et al
    Relative neuron loss in hippocampal sclerosis of aging and Alzheimer disease.
    Ann Neurol. 2018 Sep 24. doi: 10.1002/ana.25344.
    PubMed     Abstract available


  51. VERBERK IMW, Slot RE, Verfaillie SCJ, Heijst H, et al
    Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes.
    Ann Neurol. 2018 Sep 9. doi: 10.1002/ana.25334.
    PubMed     Abstract available


    July 2018
  52. VECCHIO F, Miraglia F, Iberite F, Lacidogna G, et al
    Sustainable method for Alzheimer's prediction in Mild Cognitive Impairment: EEG connectivity and graph theory combined with ApoE.
    Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25289.
    PubMed     Abstract available


  53. ARNOLD SE, Betensky RA
    Multi-crossover randomized controlled trial designs in Alzheimer's disease.
    Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25280.
    PubMed     Abstract available


    June 2018
  54. YU L, Petyuk VA, Gaiteri C, Mostafavi S, et al
    Targeted brain proteomics uncover multiple pathways to Alzheimer's dementia.
    Ann Neurol. 2018 Jun 16. doi: 10.1002/ana.25266.
    PubMed     Abstract available


    March 2018
  55. SHEIKH-BAHAEI N, Sajjadi SA, Manavaki R, McLean M, et al
    PET-guided MR Spectroscopy in Alzheimer's disease.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25202.
    PubMed     Abstract available


    February 2018
  56. GOETZL EJ, Schwartz JB, Abner EL, Jicha GA, et al
    High complement levels in astrocyte-derived exosomes of Alzheimer's disease.
    Ann Neurol. 2018 Feb 6. doi: 10.1002/ana.25172.
    PubMed     Abstract available


  57. TAN CH, Desikan RS
    Interpreting Alzheimer's disease polygenic scores.
    Ann Neurol. 2018 Feb 2. doi: 10.1002/ana.25164.
    PubMed    


    January 2018
  58. DONG Y, Lagarde J, Xicota L, Corne H, et al
    Neutrophil hyperactivation correlates with Alzheimer's disease progression.
    Ann Neurol. 2018 Jan 25. doi: 10.1002/ana.25159.
    PubMed     Abstract available


  59. WHITWELL JL, Graff-Radford J, Tosakulwong N, Weigand SD, et al
    [(18) F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease.
    Ann Neurol. 2018 Jan 11. doi: 10.1002/ana.25142.
    PubMed     Abstract available


  60. BAGI Z, Brandner DD, Le P, McNeal DW, et al
    Vasodilator dysfunction and oligodendrocyte dysmaturation in aging white matter.
    Ann Neurol. 2018;83:142-152.
    PubMed     Abstract available


  61. BOYLE PA, Yu L, Wilson RS, Leurgans SE, et al
    Person-specific contribution of neuropathologies to cognitive loss in old age.
    Ann Neurol. 2018;83:74-83.
    PubMed     Abstract available


  62. LUCEY BP, Hicks TJ, McLeland JS, Toedebusch CD, et al
    Effect of sleep on overnight cerebrospinal fluid amyloid beta kinetics.
    Ann Neurol. 2018;83:197-204.
    PubMed     Abstract available


    November 2017
  63. CHRISTOPHER L, Napolioni V, Khan RR, Han SS, et al
    A variant in PPP4R3A protects against Alzheimer-related metabolic decline.
    Ann Neurol. 2017 Nov 11. doi: 10.1002/ana.25094.
    PubMed     Abstract available


    October 2017
  64. VEMURI P, Lesnick TG, Przybelski SA, Knopman DS, et al
    Age, Vascular Health, and Alzheimer's disease Biomarkers in an Elderly Sample.
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25071.
    PubMed     Abstract available


    September 2017
  65. BOROS BD, Greathouse KM, Gentry EG, Curtis KA, et al
    Dendritic spines provide cognitive resilience against Alzheimer's disease.
    Ann Neurol. 2017 Sep 16. doi: 10.1002/ana.25049.
    PubMed     Abstract available


  66. TAN CH, Hyman BT, Tan JJX, Hess CP, et al
    Polygenic hazard scores in preclinical Alzheimer disease.
    Ann Neurol. 2017;82:484-488.
    PubMed     Abstract available


    August 2017
  67. IRWIN DJ, Lleo A, Xie SX, McMillan CT, et al
    Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.
    Ann Neurol. 2017;82:247-258.
    PubMed     Abstract available


    July 2017
  68. ESCOTT-PRICE V, Myers AJ, Huentelman M, Hardy J, et al
    Polygenic Risk Score Analysis of Pathologically Confirmed Alzheimer's Disease.
    Ann Neurol. 2017 Jul 20. doi: 10.1002/ana.24999.
    PubMed     Abstract available


    June 2017
  69. VASSILAKI M, Christianson TJ, Mielke MM, Geda YE, et al
    Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals.
    Ann Neurol. 2017;81:871-882.
    PubMed     Abstract available


    May 2017
  70. MARTISKAINEN H, Herukka SK, Stancakova A, Paananen J, et al
    Decreased plasma beta-amyloid in the Alzheimer's disease APP A673T variant carriers.
    Ann Neurol. 2017 May 26. doi: 10.1002/ana.24969.
    PubMed     Abstract available


  71. TIJMS BM, Bertens D, Slot RE, Gouw AA, et al
    Low normal cerebrospinal fluid Abeta42 levels predict clinical progression in nondemented subjects.
    Ann Neurol. 2017;81:749-753.
    PubMed     Abstract available


    April 2017
  72. MENG Y, Volpini M, Black S, Lozano AM, et al
    Focused ultrasound as a novel strategy for Alzheimer's disease therapeutics.
    Ann Neurol. 2017 Apr 10. doi: 10.1002/ana.24933.
    PubMed     Abstract available


  73. HANSEEUW BJ, Betensky RA, Schultz AP, Papp KV, et al
    Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline.
    Ann Neurol. 2017;81:583-596.
    PubMed     Abstract available


  74. ABNER EL, Kryscio RJ, Schmitt FA, Fardo DW, et al
    Outcomes after diagnosis of mild cognitive impairment in a large autopsy series.
    Ann Neurol. 2017;81:549-559.
    PubMed     Abstract available


    March 2017
  75. SPINELLI EG, Mandelli ML, Miller ZA, Santos-Santos MA, et al
    Typical and atypical pathology in primary progressive aphasia variants.
    Ann Neurol. 2017;81:430-443.
    PubMed     Abstract available


    December 2016
  76. MARQUIE M, Normandin MD, Meltzer AC, Siao Tick Chong M, et al
    Pathologic correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies.
    Ann Neurol. 2016 Dec 20. doi: 10.1002/ana.24844.
    PubMed     Abstract available


    November 2016
  77. KANTARCI K, Lowe VJ, Boeve BF, Senjem ML, et al
    AV-1451 Tau and beta-Amyloid PET Imaging in Dementia with Lewy Bodies.
    Ann Neurol. 2016 Nov 18. doi: 10.1002/ana.24825.
    PubMed     Abstract available


    October 2016
  78. ALBERS AD, Asafu-Adjei J, Delaney MK, Kelly KE, et al
    Episodic Memory of Odors Stratifies Alzheimer Biomarkers in Normal Elderly.
    Ann Neurol. 2016 Oct 1. doi: 10.1002/ana.24792.
    PubMed     Abstract available


  79. VOSSEL KA, Ranasinghe KG, Beagle AJ, Mizuiri D, et al
    Incidence and Impact of Subclinical Epileptiform Activity in Alzheimer's Disease.
    Ann Neurol. 2016 Oct 1. doi: 10.1002/ana.24794.
    PubMed     Abstract available


    August 2016
  80. BAYKARA E, Gesierich B, Adam R, Tuladhar AM, et al
    A novel imaging marker for small vessel disease based on skeletonization of white matter tracts and diffusion histograms.
    Ann Neurol. 2016 Aug 12. doi: 10.1002/ana.24758.
    PubMed     Abstract available


    July 2016
  81. TIRABOSCHI P, Corso A, Guerra UP, Nobili F, et al
    123 I-FP-CIT SPECT and 123 I-MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from other dementias: a comparative study.
    Ann Neurol. 2016 Jul 11. doi: 10.1002/ana.24717.
    PubMed     Abstract available


    April 2016
  82. MATIAS-GUIU JA, Cabrera-Martin MN, Oreja-Guevara C, Carreras JL, et al
    PiB and other amyloid-PET tracers for the study of white matter and multiple sclerosis.
    Ann Neurol. 2016 Apr 21. doi: 10.1002/ana.24666.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: